STAT3 and plasma cell myeloma: Recent preclinical studies demonstrate that IL‐6/JAK‐STAT3 axis inhibition reduces myeloma cell viability while normalizing inflammation‐associated metabolic disturbances, supporting its therapeutic potential in precursor states [25, 32].